Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1215624 | 0.85 | ABCB1 (0.39) | CYP1A2CYP2D6HTTABCB1 | |
| SCHEMBL6468216 | 0.81 | CYP1A2 (0.52) | CYP1A2CYP2D6HTTMEN1KMT2A | |
| SCHEMBL12898793 | 0.80 | HTT (0.39) | CYP1A2HTTALDH1A1TSHRKDM4E | |
| SCHEMBL12884817 | 0.79 | HTT (0.40) | CYP1A2HTTALDH1A1TSHRKDM4E | |
| SCHEMBL13691205 | 0.79 | HTT (0.38) | CYP1A2HTTALDH1A1TSHRKDM4E | |
| SCHEMBL13691187 | 0.79 | HTT (0.40) | CYP1A2HTTALDH1A1TSHRKDM4E | |
| SCHEMBL5987499 | 0.77 | HTT (0.38) | CYP1A2HTTMEN1ALDH1A1TSHR | |
| SCHEMBL9461101 | 0.76 | HTT (0.50) | CYP1A2HTTMEN1ALDH1A1TSHR | |
| SCHEMBL1936439 | 0.75 | HTT (0.44) | HTTMEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL1178054 | 0.74 | MAPT (0.43) | MEN1ALDH1A1KMT2AKDM4EABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718679-B2 | Heteroaryl carboxamides | HOFFMAN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718679-B2 | Heteroaryl carboxamides | HOFFMAN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718679-B2 | Heteroaryl carboxamides | HOFFMAN-LA ROCHE INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| EP-2076511-A1 | NOVEL HETEROARYL CARBOXAMIDES | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| EP-1487828-B1 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008049747-A1 | NOVEL HETEROARYL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008049747-A1 | NOVEL HETEROARYL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-02 | — | — | WO | disclosed |
| US-20080103143-A1 | NOVEL HETEROARYL CARBOXAMIDES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| US-20080103143-A1 | NOVEL HETEROARYL CARBOXAMIDES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| US-20080103143-A1 | NOVEL HETEROARYL CARBOXAMIDES | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| US-20060063765-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103143-A1 | NOVEL HETEROARYL CARBOXAMIDES | F12, F11, F2 | CYP1A2 120/4885CYP2D6 695/4885HTT 3572/4885 |
| US-20060063765-A1 | Novel compounds | CCR3, NSUN3, CCR1 | CYP1A2 2390/4885CYP2D6 2472/4885HTT 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.